UPDATE: Morgan Stanley Starts Centessa Pharmaceuticals (CNTA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Centessa Pharmaceuticals (CNTA): Analysts Initiate With 'Buy' on 'Broad Pipeline With Significant Optionality'
June 22, 2021 8:35 AM EDTWall Street analysts have kicked off coverage of Centessa Pharmaceuticals (NASDAQ: CNTA) with a rating equivalent to Buy. So far, analysts at Jefferies, Goldman Sachs, and Morgan Stanley are all positive on the stock.
Centessa Pharmaceuticals secured $330 million in an initial public offering (IPO) in May in a bid to continue with its plan of reshaping the traditional drug development process.
The company initially intended to offer 15 million of its depositary shares in the IPO, priced between $18 and $20 per share. However, Contessa later raised the number of offered shares to 16.5 million,... More
Goldman Sachs Starts Centessa Pharmaceuticals (CNTA) at Buy
June 22, 2021 1:17 AM EDTGoldman Sachs analyst Salveen Richter initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $42.00.
The analyst comments "CNTA is an umbrella company reimagining the R&D model and leveraging asset centricity at scale (ten... More
UPDATE: Jefferies Starts Centessa Pharmaceuticals (CNTA) at Buy
June 22, 2021 12:24 AM EDT(Updated - June 22, 2021 7:53 AM EDT)
Jefferies analyst Eun Yang initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $35.00.
The analyst commented, "As a holding company with 10 distinct subsidiaries, CNTA's broad pipeline in diverse therapeutic... More
